IL-LITERA-FIRM
29.6.2021 15:02:08 CEST | Business Wire | Press release
The Litera Firm Intelligence business unit, developer of the Foundation data platform, and Wilson Allen, a leading provider of software, services, and consulting expertise to help law firms manage the entire client engagement lifecycle, today announced a strategic partnership. The partnership formalizes Wilson Allen as a technical implementation partner for the Foundation Firm Intelligence platform.
The Foundation Firm Intelligence platform breaks down data silos, combining information from disparate systems like CRM, Time and Billing, HR, conflicts, and external sources to provide a strategic view of law firm clients, including what work a firm has done for a client, who did the work, and all the third parties involved.
As a Foundation services partner, Wilson Allen will assist firms with implementing the Firm Intelligence platform and with associated strategic consulting, integration services, and data management services as needed.
“We’ve talked to several firms who are moving beyond the acronym of CRM when implementing solutions to better understand their client relationships across the client and matter lifecycle. Firm intelligence fits into a larger definition of business development strategy,” explained Michael Warren, Vice President and head of Wilson Allen’s Client Development and Intake practice. “Helping these firms implement Foundation is a natural fit for Wilson Allen, given our deep experience advising law firms on how to leverage their systems and data for competitive advantage. The company’s client development practice assists firms with software selection, data strategy and data migration, software implementation, technology training and change management.
“We’re seeing a growing need for business development and CRM expertise as firms move to leverage their Firm Intelligence platform for strategic relationship management,” said Barry Solomon, Litera Vice President for the Firm Intelligence business unit. “We are thrilled to partner with Wilson Allen to lead these Foundation projects. Michael Warren and his team bring tremendous depth and breadth across the business development domain and other system data and processes required to accelerate the business of law.”
About Litera Firm Intelligence Business Unit
Litera is the leading provider of software for law firms and document-intensive organizations across the globe, helping them satisfy the demands of clients. Part of the Firm Intelligence business unit, Foundation enables large law firms to transform their disparate data about clients, matters, people, and parties into usable and actionable information. The Foundation data platform includes integrated applications for Experience Management, Expertise Location, and Strategic Relationship Management – leveraging firm knowledge to win new business, improve client service, and gain insight into both the business and practice of law.
https://www.litera.com/
About Wilson Allen
Wilson Allen offers software, consulting, and technical services that enable law firms and professional services organizations to achieve better business performance. The company partners with leading industry solution providers to help firms identify and win more business, manage risk, deliver profitable engagements, and develop and implement performance analytics to enable more strategic and profitable operations.
https://wilsonallen.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005602/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom